Psoriatic arthritis drug risankizumab improves skin and joints in the long-term, trial suggests
Treatment with risankizumab can work well for people with psoriatic arthritis on a long-term basis, says research presented at a European conference.
Psoriatic arthritis is a type of arthritis that affects some people with the skin condition psoriasis. It typically causes affected joints to become stiff, swollen and painful.
Treatment usually involves trying different medicines until the symptoms reduce. Ideally, a patient will take one medicine that treats both the psoriasis and psoriatic arthritis.
Risankizumab is currently available on the NHS as a treatment for psoriatic arthritis who have had an inadequate response or who have been intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). And with good reason, says new data.
Clinical trials have already showed that Risankizumab was effective over a 24-week period. Now a look at the longer-term impact – 100 weeks – suggests that “risankizumab is indeed a competent treatment for psoriatic arthritis and that the effect might appreciate is maintained in the long term,” according to Dr Kim Papp, one of the study’s investigators.
PS Did you know that Arthritis Digest Magazine is labelled the best UK Arthritis blog from thousands of blogs on the web ranked by traffic, social media followers, domain authority & freshness?
